ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ATHX Athersys Inc

0.1018
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Athersys Inc NASDAQ:ATHX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.1018 0.101 0.104 0 01:00:00

HEALIOS K.K. Increases Investment in Athersys by Fully Exercising Warrant to Acquire Additional Shares

30/03/2020 11:00am

Business Wire


Athersys (NASDAQ:ATHX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Athersys Charts.

Athersys, Inc. (“Athersys”) (NASDAQ: ATHX) announced today that its partner in Japan, HEALIOS K.K. (“Healios”), exercised in full its warrant to purchase shares of Athersys common stock. Healios purchased 4,000,000 shares at a price of $1.76 per share in accordance with the terms of the warrant, representing an additional investment of $7,040,000 in Athersys.

This warrant was issued to Healios in March 2018 as part of an expansion of the collaboration between the companies. This expansion agreement set the warrant exercise price at 110% of the average price per share over the ten days preceding exercise, or $1.76 per share so long as the reference price remained below this floor.

Healios previously purchased 12,000,000 shares of Athersys common stock and now owns approximately 9.4% of the current outstanding shares of Athersys. There are no other warrants outstanding.

About Athersys

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization. More information is available at www.athersys.com. Follow Athersys on Twitter at www.twitter.com/athersys.

Ivor Macleod Chief Financial Officer Tel: (216) 431-9900 ir@athersys.com

Karen Hunady Director of Corporate Communications & Investor Relations Tel: (216) 431-9900 khunady@athersys.com

David Schull Russo Partners, LLC Tel: (212) 845-4271 or (858) 717-2310 David.schull@russopartnersllc.com

1 Year Athersys Chart

1 Year Athersys Chart

1 Month Athersys Chart

1 Month Athersys Chart

Your Recent History

Delayed Upgrade Clock